Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Naruhiko Mizuta is active.

Publication


Featured researches published by Naruhiko Mizuta.


Xenotransplantation | 1998

The molecular mechanism of apoptosis induced by xenogeneic cytotoxicity

Ikuya Fujiwara; Hiroo Nakajima; Hisakaru Yamagishi; Tetsuro Matsuda; Naruhiko Mizuta; Takahiro Oka

Abstract: In order to clarify the role of natural killer (NK) cells in delayed xenograft rejection (DXR) of discordant xenotransplantation, we used in vitro xenogeneic combination of human NK cells and pig kidney target cells (PK13, and investigated the mechanism of xenogeneic cytotoxicity caused by human NK cells. In the presence of decomplemented human serum or human IgG, freshly isolated human peripheral blood lymphocytes (PBLs) caused both membrane (51Cr release) and DNA (3H release) damage on PK15. In contrast, only membrane damage was detected in the presence of normal human serum. To clarify the participation of perforin/granzymes‐cell mediated cytotoxicity (P/G‐CMC), when EGTA or concanamycin B (CMB) was added to the cytotoxicity assays, both cytotoxicities were completely inhibited by these drugs in a dose‐dependent manner. In terms of the involvement of Fas/FasL‐based cytotoxicity (F‐CMC), while the cytotoxicity assays were performed in the presence of antagonistic anti‐human FasL mAb, this antibody was not able to block the cytotoxicity. From these results, it is concluded that xenogeneic cytotoxicity is due to NK cell dependent ADCC (antibody‐dependent cell‐mediated cytotoxicity), and their effector mechanism can cause apoptosis on target cells via P/G‐CMC.


Annals of Surgery | 2009

Video-assisted skin-sparing breast-conserving surgery for breast cancer and immediate reconstruction with autologous tissue.

Hiroo Nakajima; Ikuya Fujiwara; Naruhiko Mizuta; Koichi Sakaguchi; Yasushi Hachimine

Objective:To analyze therapeutic results of video-assisted breast-conserving surgery (VA-BCS) for early stage breast cancer. Background:VA-BCS for breast cancer has been developed in Japan, and is indicated for breast cancer unaccompanied by skin involvement. The surgical incision is made at an inconspicuous site, followed by skin-sparing partial mastectomy (SSPM) and immediate reconstruction of the breast. This technique affords good cosmetic results. The long-term results are reported herein. Methods:VA-BCS was performed on 551 patients. The skin incision was made as a peri-areolar incision or at the midaxillary line. Skin-sparing partial mastectomy was performed using an endoscope and the lifting and tunneling method. Morbidity, curability, and degree of satisfaction with regard to cosmesis were analyzed. Results:Skin necrosis in 22 patients (4.0%) and necrosis of fatty tissue-muscle flap in 17 patients (3.1%) were recorded as postoperative complications. No other serious complications were encountered. Local recurrence occurred in 23 patients (4.2%) after a mean follow-up of 38.4 months. Distant-metastasis-free survival rate at 66 months was 100% for Tis, 95.5% for T1, and 90.7% for T2. Overall survival rate was 100% for Tis, 97.3% for T1, and 95.7% for T2. Degree of satisfaction with surgery as investigated by questionnaire was “good” for 76.1% of patients. Conclusion:VA-BCS for early stage breast cancer showed no association with increases in local or distant organ recurrence. The technique yielded improved cosmesis and a high degree of patient satisfaction. Follow-up observation of patients for a longer period is necessary, but VA-BCS seems useful for local treatment of breast cancer.


The Journal of Antibiotics | 2007

Aberrant Expression of Fra-1 in Estrogen Receptor-negative Breast Cancers and Suppression of their Propagation In Vivo by Ascochlorin, an Antibiotic that Inhibits Cellular Activator Protein-1 Activity

Hiroo Nakajima; Naruhiko Mizuta; Koichi Sakaguchi; Ikuya Fujiwara; Mitsuhiko Mizuta; Chiharu Furukawa; Young-Chae Chang; Junji Magae

Estrogen receptor-negative breast cancers generally are highly malignant, resistant to chemotherapy and poorly prognostic. Here we demonstrate that estrogen receptor-negative human breast cancer cell lines highly express Fra-1, c-Fos and c-Jun, components of the transcription factor, activator protein-1 (AP-1). Retrospective observation of breast cancer tissues obtained by core needle biopsy before surgery from stages II and III patients demonstrates that Fra-1 expression is high in estrogen receptor-negative human breast cancers, and negatively correlated to paclitaxel sensitivity. Ascochlorin, which suppresses cellular AP-1 activity, selectively kills estrogen receptor-negative human and mouse breast cancer cell lines, and prolongs the survival time of mice implanted with an estrogen receptor-negative mammary carcinoma. These results suggest that chemotherapy targeting AP-1 activity is a potent strategy for estrogen receptor-negative human breast cancers.


Breast Cancer | 2008

Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods

Hiroo Nakajima; Naruhiko Mizuta; Koichi Sakaguchi; Ikuya Fujiwara; Atsushi Yoshimori; Satoshi Takahashi; Ryoko Takasawa; Sei-ichi Tanuma

An antagonistic peptide called HRAP that binds to the human HER2 molecule was designed by our computational method. In silico docking study demonstrated the specific interaction of HRAP with the dimerization domain in the HER2 molecule. Interestingly, HRAP inhibited proliferation of HER2-overexpressed human breast cancer cell lines. However, it had little cellular cytotoxicity (apoptosis inducibility). The cell proliferation inhibition was associated with the suppression of phosphorylation of PTEN and Akt. Thus, HRAP is the first HER2-binding small peptide antagonist rationally designed by a computer-aided SBDD method and is useful for the development of peptide mimetics to generate novel anti-breast cancer drugs.


Biomedicine & Pharmacotherapy | 2002

Section 5. Breast: Video-assisted total glandectomy and immediate reconstruction for breast cancer

Hiroo Nakajima; Kouichi Sakaguchi; Naruhiko Mizuta; T. Hachimine; Shinya Ohe; Kiyoshi Sawai

This paper describes a new surgical technique and our clinical experience with video-assisted endoscopic total glandectomy via a middle axillary incision followed by immediate reconstruction with latissimus dorsi muscle flap (LDMF) performed in 17 patients with bigger, multiple tumors or extensive ductal spread of breast cancer. The novel techniques in this procedure are as follows: (1) By securing patients in a semi-lateral position and suspending the upper extremity, either supine or semi-lateral position can be easily achieved by simply rotating the operating table, resulting in a wider working space from the axillary to hip area. (2) By applying a retractor for skin flap traction, endoscopic glandectomy and reconstruction become safe and reliable. As a result, the mean number and size of tumors were 1.2 and 4.12 cm, respectively. Surgical margins of all the cases were pathologically negative and there were no recurrences observed during 14 months follow-up to date. Esthetic results have been satisfactory and the surgical wounds were not visible from the front in any case. Compared to mastectomy, this procedure shows the same therapeutic results, but offers a greater esthetic and psychological advantage to all the patients.


Oncogene | 2000

Caspase-dependent apoptosis by ectopic expression of E2F-4

Young-Chae Chang; Hiroo Nakajima; Sharon Illenye; Yun-Sik Lee; Nobuko Honjo; Tazuko Makiyama; Ikuya Fujiwara; Naruhiko Mizuta; Kiyoshi Sawai; Kaname Saida; Youji Mitsui; Nicholas H. Heintz

E2F is a family of transcription factors which regulates cell cycle and apoptosis of mammalian cells. E2F-1-3 localize in the nucleus, and preferentially bind pRb, while E2F-4 and 5 have no nuclear localization signal and preferentially bind p107/p130. E2F-6 suppresses the transcriptional activity of other E2F proteins. DP-1 and 2 are heterodimeric partners of each E2F protein. Using tetracycline-responsive promoters, here we compared the effects of ectopic expression of E2F-1, DP-1 and E2F-4 on cell cycle progression and apoptosis in Chinese hamster cell lines. We found that E2F-4, as well as DP-1 and E2F-1, induced growth arrest and caspase-dependent apoptosis. E2F-4 did not have a marked effect on cell cycle progression, while E2F-1 induced DNA synthesis of resting cells and DP-1 arrested cells in G1. Ectopic expression of E2F-4 did not activate E2F-dependent transcription. Our results suggest that expression of E2F-4 at elevated levels induces growth arrest and apoptosis of mammalian cells through a mechanism distinct from E2F-1 and DP-1.


World Journal of Surgical Oncology | 2012

Myoid hamartoma of the breast that proved difficult to diagnose: a case report

Naruhiko Mizuta; Koichi Sakaguchi; Mitsuhiko Mizuta; Aya Imai; Katsuhiko Nakatsukasa; Midori Morita; Mari Soshi; Mariko Goto; Satoru Yasukawa; Eiichi Konishi; Tetsuya Taguchi

Myoid hamartomas of the breast are extremely rare breast lesions, with a poorly understood pathogenesis. We describe the case of a 38-year-old premenopausal woman who presenting with a mass in the left breast. Mammography revealed an oval mass that was partly indistinct, and ultrasonography showed a hypoechoic mass with a slightly irregular margin. Bilateral breast dynamic magnetic resonance imaging was performed for a more detailed evaluation. The images showed rapid initial enhancement and a microlobulated margin. Because the suspicion of malignancy was strong at that time, core needle biopsy was performed. Histologically, the tumor was identified as fibroadenoma. A case of myoid hamartoma of the breast that proved difficult to diagnose is reported, and discussed with reference to the literature.


Journal of Bioscience and Bioengineering | 2010

Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP

Hiroo Nakajima; Naruhiko Mizuta; Koichi Sakaguchi; Ikuya Fujiwara; Atsushi Yoshimori; Sei-ichi Tanuma

HRAP, a pentapeptide designed to bind with the pertuzumab interacting site in an extracellular domain of the HER2 molecule, enhanced the cytotoxicity of paclitaxel in HER2-overexpressing human breast cancer cell lines, BT474 and SKBR-3, but not in MDA-231 cells, which express lower levels of HER2. HRAP enhanced mitochondria-dependent apoptosis induced by paclitaxel in SKBR-3 and BT-474, but not in MDA-231. HRAP enhanced the inhibition of phosphorylation of serine 473 in Akt and Ser380/Thy382/The383 in PTEN. These results suggest that HRAP enhances paclitaxel-induced apoptosis in a manner dependent on the PTEN/Akt signal transduction pathway.


Journal of Clinical Oncology | 2008

Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining

Ikuya Fujiwara; Hiroo Nakajima; Naruhiko Mizuta; Kouichi Sakaguchi; Y. Hachimine

1122 Background: We classified Japanese breast cancer patients based on estrogen receptor (ER), progesterone receptor (PR) and HER2 protein expression and compared their prognoses. Methods: Background and prognostic factors were compared among 600 patients with breast cancer who were assigned to groups as follows: luminal A (ER+ and/or PR+ and HER2-; n = 431; 71.8%), luminal B (ER+ and/or PR+ and HER2+; n =27; 4.5%), HER2 subtype (ER-, PR- and HER2+; n = 39; 6.5%) and basal-like breast cancer (BBC) (ER-, PR- and HER2-; n = 103; 17.2%). Results: There were no differences among the groups regarding to age, menopausal state, size of tumors, and axillary metastasis. Disease-free survival rates were significantly lower for the luminal B, HER2 subtype and BBC, than for the luminal A subtype. Cancer tended to recur earlier and overall survival was significantly lower for the BBC, than that for the luminal A and HER2 subtype. Luminal B and HER2 subtype revealed same overall survival rate as luminal A. Conclusions...


American Journal of Respiratory and Critical Care Medicine | 2001

Fas/FasL-dependent Apoptosis of Alveolar Cells after Lipopolysaccharide-induced Lung Injury in Mice

Yoshihiro Kitamura; Satoru Hashimoto; Naruhiko Mizuta; Atsuko Kobayashi; Kunihiko Kooguchi; Ikuya Fujiwara; Hiroo Nakajima

Collaboration


Dive into the Naruhiko Mizuta's collaboration.

Top Co-Authors

Avatar

Hiroo Nakajima

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Ikuya Fujiwara

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Koichi Sakaguchi

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Takahiro Oka

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Kouichi Sakaguchi

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Yasushi Hachimine

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Katsuhiko Nakatsukasa

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Kiyoshi Sawai

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Hisakazu Yamagishi

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Akio Yanagisawa

Kyoto Prefectural University of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge